Spyre Therapeutics (SYRE) Cash & Equivalents (2015 - 2026)

Spyre Therapeutics (SYRE) has 12 years of Cash & Equivalents data on file, last reported at $97.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 107.66% year-over-year to $97.2 million; the trailing twelve-month figure through Mar 2026 stood at $97.2 million (up 107.66% YoY), and the FY2025 full-year result was $85.7 million, down 2.29% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $97.2 million, up from $85.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $235.4 million in Q2 2023 and bottomed at $14.6 million in Q1 2022.
• The 5-year median for Cash & Equivalents is $69.9 million (2024), against an average of $87.2 million.
• The widest annual swing landed in 2022, when Cash & Equivalents slumped 81.76%; it then surged 545.67% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $34.9 million in 2022, then soared by 441.82% to $188.9 million in 2023, then tumbled by 53.55% to $87.7 million in 2024, then retreated by 2.29% to $85.7 million in 2025, then gained by 13.37% to $97.2 million in 2026.
• The last three Cash & Equivalents figures came in at $97.2 million (Q1 2026), $85.7 million (Q4 2025), and $64.9 million (Q3 2025), per Business Quant data.

Peer Comparison